What is Flyte?
Flyte by Pelvital USA offers a groundbreaking approach to pelvic floor therapy, primarily targeting stress urinary incontinence. Their flagship product is an FDA-cleared intravaginal device that employs mechanotherapy to stimulate cellular healing and improve bladder function, providing a convenient at-home treatment. The company's comprehensive solution extends beyond the device to include a supportive mobile application and access to pelvic health experts, aiming to deliver a holistic and effective non-surgical alternative for women experiencing incontinence. Flyte's commitment to clinical research and expert recommendations positions it as a key player in the burgeoning femtech and women's health market.
How much funding has Flyte raised?
Flyte has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2024): $5M with participation from VisionTech Partners, Pier 70 Ventures, Life Science Angels, Boomerang Ventures, Blue Pacific Fund, and Wisconsin Investment Partners
Key Investors in Flyte
VisionTech Partners
VisionTech Partners is an angel investing network that focuses on early-stage and early-growth companies, known for its rigorous due diligence and strategic capital investment in promising startups.
Pier 70 Ventures
Pier 70 Ventures invests in impact-driven technologies, particularly in healthcare, providing capital and mentorship to accelerate high-growth sustainable companies.
Life Science Angels
Life Science Angels is a prominent angel investment group dedicated to supporting early-stage companies within the life sciences sector, recognized for its significant contributions to the industry.
What's next for Flyte?
With this substantial backing, Flyte is poised to expand its product development, enhance its technological offerings, and broaden its market reach. The strategic investment signals a strong belief in Flyte's potential to disrupt the traditional treatment landscape for pelvic floor disorders. Future initiatives will likely focus on scaling manufacturing, increasing marketing efforts to reach a wider audience, and potentially exploring new therapeutic applications for their innovative technology. The company's trajectory suggests a move towards broader commercialization and establishing a dominant presence in the pelvic health industry.
See full Flyte company page
